VCEL: Vericel Corporation Stock

by  •  • Comments Off on VCEL: Vericel Corporation Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 2,223.76
Enterprise Value ($M) 2,154.67
Book Value ($M) 225.95
Book Value / Share 4.68
Price / Book 9.84
NCAV ($M) 77.93
NCAV / Share 1.61
Price / NCAV 28.54

Profitability (mra)
Return on Invested Capital (ROIC) -0.01
Return on Assets (ROA) -0.01
Return on Equity (ROE) -0.02

Liquidity (mrq)
Quick Ratio 4.21
Current Ratio 4.49

Balance Sheet (mrq) ($M)
Current Assets 205.63
Assets 353.66
Liabilities 127.70
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 197.52
Operating Income -6.46
Net Income -3.18
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 35.31
Cash from Investing -3.13
Cash from Financing 3.62

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Rtw Investments, Lp 6.70 3.64
02-14 13G/A Brown Capital Management Llc 14.29 -1.63
02-13 13G/A Vanguard Group Inc 7.07 2.00
01-25 13G/A State Street Corp 5.58 -20.79
01-22 13G/A BlackRock Inc. 16.60 6.68
01-05 13G/A Conestoga Capital Advisors, LLC 5.23 0.65

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K
2023-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2023 ☐ TRANSITION REPORT PURSUAN
2023-08-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO
2023-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 37,287 170,638 21.85
2024-04-25 28,876 131,870 21.90
2024-04-24 31,997 108,471 29.50
2024-04-23 48,729 160,614 30.34

(click for more detail)

Similar Companies
TVTX – Travere Therapeutics, Inc. URGN – UroGen Pharma Ltd.
VAXX – Vaxxinity, Inc. VERA – Vera Therapeutics, Inc.
VNDA – Vanda Pharmaceuticals Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Vericel Corporation